TLSI
NASDAQ · Biotechnology
Trisalus Life Sciences Inc
$2.43
-0.09 (-3.57%)
Open$2.61
Previous Close$2.52
Day High$2.67
Day Low$2.23
52W High$7.95
52W Low$2.20
Volume—
Avg Volume435.3K
Market Cap155.48M
P/E Ratio—
EPS$-0.49
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+78.2% upside
Current
$2.43
$2.43
Target
$4.33
$4.33
$2.61
$4.33 avg
$5.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 76.23M | 47.23M | 45.65M |
| Net Income | -66,230,030 | -3,256,844 | -3,940,718 |
| Profit Margin | -86.9% | -6.9% | -8.6% |
| EBITDA | -44,437,016 | -4,196,050 | -4,663,249 |
| Free Cash Flow | — | -5,024,799 | -4,621,021 |
| Rev Growth | — | +7.1% | +0.6% |
| Debt/Equity | 0.20 | 1.07 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $295.03 | +0.20% | 50.3 | 520.47B |
| AMGN | Amgen Inc | $465.67 | -0.30% | 26.9 | 252.64B |
| GILD | Gilead Sciences Inc | $168.08 | +0.08% | — | 208.95B |
| VRTX | Vertex Pharmaceuticals Inc | $538.60 | -0.74% | 33.9 | 134.82B |
| REGN | Regeneron Pharmaceuticals | $955.47 | +0.45% | 20.4 | 98.38B |
| ALNY | Alnylam Pharmaceuticals Inc | $165.04 | +5.36% | 7.7 | 20.98B |